

Gilead ESICM LIVES 2022 Symposium

LIVE

Date: 25th October 2022

Time: 12:30-13:30 CEST

Location: Amphitheatre Havane

EVERY HOUR COUNTS - TIMELY INITIATION OF ANTIFUNGAL TREATMENT IN ICU PATIENTS

Invasive fungal infections (IFIs) are hidden killers, causing approximately 1.7 million deaths each year.¹

With increasing numbers of at-risk patients and a multitude of risk factors in the ICU setting, it is vital to be aware that your patients in a critical condition may be vulnerable to fungal infections.²⁻¹⁶ Each day that an IFI is missed can reduce the chance of survival.²⁻³

Diagnosis of IFIs can be challenging, but every hour counts.^{2,3,15-21} Join us for the ESICM 2022 Symposium to hear expert speakers discuss how early identification of high-risk patients is key to the timely initiation of treatment to reduce mortality risk from IFIs.^{2,3,11,22-26}

Our expert speakers



Assoc. Professor Martin Hoenigl,
MD, FECMM

Associate Professor of Medicine at the Division of Infectious Diseases of the University of California, San Diego, and the Section of Infectious Diseases and the Division of Pulmonology, Medical University of Graz, Austria.




Professor Ignacio Martin-Loeches,
MD, PhD, JFICMI

Professor at the School of Medicine at Trinity College Dublin, Ireland and an Associate Professor at the Department of Respiratory Medicine in Barcelona, Spain. He is a consultant in Intensive Care Medicine at St James's Hospital, Ireland.

Symposium agenda

Start 12:30	Welcome, introductions and overview of agenda	Martin Hoenigl (Austria)
12:33-12:56	Risk factors in ICU patients that drive fungal disease	Martin Hoenigl (Austria)
12:56-13:19	Every hour counts: Timely initiation of antifungal treatment in ICU patients	Ignacio Martin-Loeches (UK)
13:19-13:29	Q&A	All
Finish 13:30	Summary and close	Martin Hoenigl (Austria)



This session is organised and funded by Gilead Sciences Europe, Ltd. This session will contain promotional content. This material is intended for healthcare professionals only. Prescribing information and adverse event reporting instructions will be available at the end of the symposium

References:

1. Kainz K *et al.* *Microb Cell.* 2020;**7**(6):143-145. 2. Morrell M *et al.* *Antimicrob Agents Chemother.* 2005;**49**(9):3640-3645. 3. Pappas PG *et al.* *Nat Rev Dis Primers.* 2018;**4**:18026. 4. Chatelon J *et al.* *Adv Ther.* 2019;**36**(12):3308-3320. 5. Bongomin F *et al.* *J Fungi (Basel).* 2017;**3**(4):57. 6. De Pascale G *et al.* *Curr Opin Crit Care.* 2015;**21**:421-429. 7. Armstrong-James D *et al.* *BMJ Case Rep.* 2020;**13**:e233072. 8. Gangneux JP *et al.* *J Mycol Méd.* 2020;**30**:100971. 9. Peman J *et al.* *Rev Iberoam Micol.* 2020;**37**(2):41-46. 10. Verma A *et al.* *Open Forum Infect Dis.* 2017;**4**(1):ofw241. 11. Cornely OA *et al.* *Clin Infect Dis.* 2007;**44**(10):1289-1297. 12. Kuse E-R *et al.* *Lancet.* 2007;**369**(9572):1519-1527. 13. Walsh TJ *et al.* *N Engl J Med.* 2002;**346**(4):225-234. 14. Walsh TJ *et al.* *N Engl J Med.* 1999;**340**(10):764-771. 15. Walsh TJ *et al.* *N Engl J Med.* 2004;**351**(14):1391-1402. 16. Horta R *et al.* *Ann Burns Fire Disasters.* 2020;**33**(2):101-106. 17. Falci DR. *Infect Dis Ther* 2017;**6**(2):213-223. 18. Lass-Flörl C and Cuenca-Estrella M. *J Antimicrob Chemother.* 2017;**72**(Suppl. 1):i5-11. 19. Blot S *et al.* *Curr Opin Crit Care.* 2019;**25**(5):430-437. 20. Vandewoude KH *et al.* *Med Mycol.* 2006;**44**(Suppl.1):S71-S76. 21. Zhang H and Zhu A. *Infect Drug Res.* 2020;**13**:607-615. 22. Chamitos G *et al.* *Clin Infect Dis.* 2008;**47**(4):503-509. 23. Cornely OA *et al.* *Mycoses.* 2011;**54**(5):e449-e455. 24. Nett JE and Andes DR. *Infect Dis Clin North Am.* 2016;**30**:51-83. 25. Chandrasekar P. *J Antimicrob Chemother.* 2011;**66**(3):457-465. 26. Almyroudis NG *et al.* *Antimicrob Agents Chemother.* 2007;**51**(7):2587-2590.

Date of preparation: September 2022. Job code: IHQ-AMB-0799